Sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia
ICD-10 F13.97 is a billable code used to indicate a diagnosis of sedative, hypnotic or anxiolytic use, unspecified with sedative, hypnotic or anxiolytic-induced persisting dementia.
F13.97 refers to a condition characterized by the use of sedative, hypnotic, or anxiolytic substances that leads to persisting dementia. This diagnosis is relevant for individuals who have developed cognitive impairment due to prolonged use of these substances, which can include benzodiazepines, barbiturates, and other sedative medications. The dementia induced by these substances is not only a result of their pharmacological effects but also reflects the neurotoxic potential of long-term use. Patients may exhibit memory deficits, impaired judgment, and difficulties in daily functioning. This code is crucial for identifying patients who require specialized treatment plans that address both their substance use disorder and cognitive deficits. Treatment may involve a multidisciplinary approach, including detoxification, cognitive rehabilitation, and psychotherapy, to manage both the addiction and the cognitive impairments effectively.
Comprehensive mental health assessments, including cognitive evaluations and substance use history.
Patients presenting with cognitive decline and a history of sedative use.
Careful monitoring of cognitive function and substance withdrawal symptoms.
Detailed substance use history, treatment plans, and progress notes.
Patients undergoing detoxification with cognitive impairments.
Integration of cognitive rehabilitation strategies into treatment.
Used when assessing cognitive function in patients with substance use disorders.
Detailed assessment notes and cognitive testing results.
Psychiatrists should document the impact of substance use on cognitive function.
F13.97 is significant as it highlights the intersection of substance use disorders and cognitive impairment, necessitating a comprehensive treatment approach that addresses both issues.
